TrialInfluenza and other respiratory viruses2015

Phase II, randomized, open, controlled study of AS03-adjuvanted H5N1 pre-pandemic influenza vaccine in children aged 3 to 9 years: follow-up of safety and immunogenicity persistence at 24 months post-vaccination.

Javier Díez-Domingo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.